BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T022137
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220613
DTEND;VALUE=DATE:20220615
DTSTAMP:20260516T022137
CREATED:20220303T102140Z
LAST-MODIFIED:20220303T102140Z
UID:33430-1655078400-1655251199@www.pharmajournalist.com
SUMMARY:Pre Filled Syringes West Coast
DESCRIPTION:SMi’s 6th Annual Conference\nPre-Filled Syringes West Coast\nJune 13 – 14\, 2022 | San Diego\, CA\, USA \nSESSING DEVICE DEVELOPMENT AND REGULATION FOR ADVANCED INNOVATION \nSMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference\, to be held in San Diego. As part of SMi’s leading series of drug delivery device conferences\, the 2022 event will provide insights into the rapidly accelerating market of combination product development with industry\, device developer and regulatory perspectives. \n \nThe last year has seen major advances in device design and development with patient usability\, ease of use and safety remaining at the forefront. This upcoming conference will assess the industry movement towards enabling self-administration through advanced device design\, innovations in connectivity to aid the user\, and the increasing importance of biologics and novel drug product considerations for device development. Furthermore\, regulatory bodies and leaders from big pharma will give an international update on the fast-evolving industry landscape. As one of our most sought-after events\, this conference is not to be missed. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nBenefits of attending: \n\nDiscover the latest advances in innovative device design for user-centric drug delivery\nAssess evolving approaches to platforms for advanced combination product portfolios\nUncover the key considerations to ensure optimal lifecycle management for drug delivery devices\nExplore how the industry is evolving with global developments including case studies of sustainable practices for drug delivery devices and the industry’s role in mass vaccination campaigns\nEngage in interactive sessions reviewing the landscape of on-body injectors for large volume delivery and the role of connectivity for wearable devices\n\nChAiRs foR 2022: \nTina Rees\, Associate Director\, Human Factors\, Regeneron Pharmaceuticals \nNatalie Abts\, Head of Human Factors Engineering\, Genentech \nFeatured 2022 speakers include:  \n\nSriman Banerjee\, Head of Packaging Development & Commercial Device Engineering\, Takeda\nAmin Sedighiamiri\, Associate Director\, Device Development\, AstraZeneca\nJames Wabby\, Executive Director\, Head of Regulatory Strategy\, Emerging Technologies and Combination Products\, Abbvie\nKhaudeja Bano\, Executive Medical Director\, Combination Product Safety Head\, Amgen\nRachel poker\, Associate Director\, Human Factors\, AstraZeneca\nKristina Li\, Sr. Engineer II\, Technical Development\, Biogen\nsujani Nannapaneni\, Human Factors Principal Research Engineer\, Combination Product Development\, Abbvie\n\nWho should attend? \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nPrevious attendees include: \nAbbott Laboratories; AbbVie; Advanced Molding Technologies; Aegerion Pharmaceuticals; Ajinomoto Althea\, Inc.; Allergan; Allergen Inc; Almac Group; Amgen; Antares Pharma; Aptar Pharma; AstraZeneca; Baxter Healthcare; BCM Group LLC; BioMarin; Boehringer Ingelheim; Connecticut Spring & Stamping; Credence MedSystems\, Inc.; Execution Metrics\, Inc; Ferring Pharmaceuticals; Fresenius-Kabi; Genentech; Genentech\, Inc.; Gilead Sciences; Glenmark Pharmaceuticals; Harro Hofliger Verpackungsmaschinen GmbH; Inovio Pharmaceuticals; iO Lifesciences; Ionis Pharmaceuticals; Ionis Pharmaceuticals\, Inc.; Matchstick; MedImmune; MedImmune LLC; Medizap; Medtronic; Merck & Co.; Mitsubishi Gas Chemical Company\, Inc; Nemera; Nipro PharmaPackaging; NOVO Engineering\, Inc.; Novo Nordisk; Novo Nordisk A/S; One World DMG; Owen Mumford; Pfenex; Pfenex Inc; Pfizer CentreOne; RAUMEDIC INC; Regeneron; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals\, Inc.; Shire; Smithers Rapra; Steri-Tek; Stevanato Group S.p.A; Subcuject ApS; Suttons Creek Inc; Terumo Corporation; Terumo Medical Corporation; Terumo Pharmaceutical Solutions; UserWise\, Inc.; W. L. Gore & Associates\, Inc.; West Pharmaceutical Services; West Pharmaceutical Services\,; West Pharmaceuticals Services Inc; Worrell; Xeris Pharmaceuticals; ZebraSCI; zebrasci inc; ZEON CORPORATION; Zeon Specialty Materials ; Zeon Specialty Materials Inc \nFind out more here: http://www.prefilled-syringes-westcoast.com/ \nSMi Group offer direct access to key decision makers through tailored sponsorship\, exhibitor and delegate packages. For details contact Daniele Moreschi on +44 7498539226  \nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: rjones@smi-online.co.uk\nFollow us: @SMiPharm #SMiPFSUSA
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2022/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260516T022137
CREATED:20220202T094402Z
LAST-MODIFIED:20220202T094440Z
UID:33099-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd HER2-Targeted Therapies Summit
DESCRIPTION:Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics\, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 ‘low’ space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before. \nAs such\, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma\, biotech and academia to unite under one roof to discuss these developments\, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients. \nAs the clinical and commercial opportunity of HER2-targeted therapies becomes apparent\, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target. \nView the full agenda now: https://ter.li/kxq80g
URL:https://www.pharmajournalist.com/event/2nd-her2-targeted-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260516T022137
CREATED:20220207T102442Z
LAST-MODIFIED:20220207T102621Z
UID:33181-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:Returning in 2022\, the 2nd Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment. \nThis is your ultimate forum to identify\, validate\, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. \nDesigned for experts working directly on myeloid-directed therapies\, and those in adjacent immuno-oncology fields\, from cell therapy to checkpoint and engager development. \nIf you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment\, this is your 500-foot view of the intricate pathways\, interactions\, and novel target development in the tumor microenvironment \nDeep-dive into myeloid biology\, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics\, Gilead Sciences\, Merck\, Verseau Therapeutics\, Carisma Therapeutics\, Pfizer and many more \nWith targets such as TREM1 and TREM2 making waves in the clinic\, analysis of CD47 candidates back-translating to next-generation therapies\, and novel dendritic cell candidates such as FTL3 in development\, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment. \nTo know more visit: https://ter.li/2067lj
URL:https://www.pharmajournalist.com/event/2nd-tumor-myeloid-directed-therapies-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR